Generics maker IGI Laboratories acquires 18 AstraZeneca drugs

25 September 2014

New Jersey-based specialty generic company IGI Laboratories (NYSE MKT: IG) has acquired regulatory rights, related documents and records for 18 of Anglo-Swedish drug major AstraZeneca (LSE: AZN), 17 of which were marketed.

The 18 products include 17 injectables and 1 suppository, and all of them have been previously approved by the US Food and Drug Administration as Abbreviated New Drug Applications or new drug applications prior to their discontinuation or withdrawal from the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK